Altamira Therapeutics (FRA:2QA) Scaled Net Operating Assets: 0.51 (As of Jun. 2025)


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics Scaled Net Operating Assets?

Altamira Therapeutics FRA:2QA 30 Scaled Net Operating Assets is 0.51 as of Jun. 2025. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Altamira Therapeutics's operating assets for the quarter that ended in Jun. 2025 was €6.18 Mil. Altamira Therapeutics's operating liabilities for the quarter that ended in Jun. 2025 was €1.97 Mil. Altamira Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was €8.26 Mil. Therefore, Altamira Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was 0.51.

Altamira Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Scaled Net Operating Assets Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.63 -0.11 1.01 0.68

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 1.02 0.74 0.76 0.51

FRA:2QA vs IOBTQ, SCPX, CARM: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Altamira Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altamira Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Scaled Net Operating Assets falls into.


FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Altamira Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(7.309-1.648)/8.385
=0.68

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=8.263 - 0.954
=7.309

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1.993 - 0.228 - 0.117
=1.648

Altamira Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2025 )
=(Operating Assets (Q: Jun. 2025 )-Operating Liabilities (Q: Jun. 2025 ))/Total Assets (Q: Dec. 2024 )
=(6.179-1.965)/8.263
=0.51

where

Operating Assets(Q: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6.182 - 0.003
=6.179

Operating Liabilities(Q: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.65 - 0.173 - 0.512
=1.965

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.51 mean?
Altamira Therapeutics (FRA:2QA) has a Scaled Net Operating Assets of 0.51 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Scaled Net Operating Assets too high?
Altamira Therapeutics' current Scaled Net Operating Assets is 0.51. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' Scaled Net Operating Assets compare to IOBTQ and SCPX?
Altamira Therapeutics' Scaled Net Operating Assets of 0.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current Scaled Net Operating Assets is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current Scaled Net Operating Assets of 0.51. The current Scaled Net Operating Assets is 0.51. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current Scaled Net Operating Assets is 0.51 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price